Medicine Introduction Center

Posts Tagged ‘Forecasts’

Shopsters Vision: The future treatment of orphan diseases – market forecasts for 2015, analysis and reimbursement
leading provider of business intelligence

, launched its latest study “The future of therapy for rare diseases – market forecasts for 2015, analysis and reimbursement” The report provides a thorough analysis unmet needs, drivers and barriers that affect the treatment of diseases of the global market for orphans. The report analyzes the markets for therapeutic orphan diseases in the United States, the first five European countries (UK, Germany, France, Italy and Spain) and Japan. The ways of dealing with the use, sale and the price is expected to 2015 for key geographic areas and to select therapeutic segments. The report also provides a benchmarking of leading companies, and also covers mergers, acquisitions and licensing agreements that shape the global marketplace.

/>
This report draws on data and information from proprietary databases, the primary and secondary research and analysis of the home by GBI investigation team of experts industry.

Field

The scope of this report includes:
– The annualized market for orphan diseases treatment market in 2000 to 2008, forecasts />
-. The analysis of therapeutic geographies orphan disease market in the world, including USA, UK, Germany, France, Italy, Spain and Japan br – characterization of the market the market of orphan diseases therapies including market size, the annual cost of treatment methods and treatment using />
– Coverage of pipeline molecules at various stages drug development
– companies leading benchmarking. Large companies studied in this report are Roche Farma, Genzyme Corporation, Novartis AG, Celgene Corporation, Orphan Europe, Pfizer Inc. and Shire Pharmaceuticals PLC
Actelion -. Main activities M & A, licensing agreements, which took place between 2008 and 2009 the global market for therapeutic orphan diseases

Reasons to buy

The report will improve their choice making. This will
– Align portfolio of products to market
with high growth potential – develop market access and market expansion strategies by identifying key therapeutic segments and geographic markets ready
to strong growth – Strengthen R & D pipeline by identifying new target mechanisms that can produce first class of molecules with greater efficiency and safety
– Develop key strategic initiatives by understanding the main areas of interest of the leading companies
– Exploit of licenses and licensing opportunities by identifying products that would fill gaps in the portfolio mentioned

Roche Pharma , Genzyme Corporation

Novartis AG Celgene Corporation

Orphan Europe Pfizer Inc.

Actelion Pharmaceuticals Shire Plc.

Contents

1 Contents 1.1 List

Tables 1.2 List of Figures
2 global market orphan diseases
Introduction 2.1 Description of the disease
2.1.1 The United States

States 2.1.2 Europe 2.1.3 Japan

Report 2.3 Overview 2.2 Market orientation 3
World Orphan Disease Therapeutics Market: Market characterization

3.1 3.2 Market Forecast by orphan disease sector
3.3 usage patterns
ill population 3.3.1 3.3.2

Seeking Diagnosis Treatment Population Population Population 3.3.4 3.3.3 recipe

3.3 0.5 Templates therapeutic

Drivers 3.4 Market Shares 3.4.2 Market Constraints 3.4.1 Geographical

3.5 Key market trends 3.5.1 Increase

portfolio of federal funds 3.5.2 3.5.3
regulatory trends – current price and the redemption scenario
World Fabry Disease Therapeutics Market Overview 4 4.1

Market 4.2 Market Forecasts 4.3 Cost
therapy averaged 4.4

4.4.2 4.4. a research treatment





Fabryzyme 4.5.2 4.5 0.1 6.4 Replagal Drug Pipeline

5 Global analysis of Pompe disease
markets Therapeutics Market 5.1 Overview 5.2

5.3 The forecast cost of the market average of 5.4 />

5.4.1 5.4.2 populations of sick people seeking treatment


order 5.4.4 Patterns of the population of the therapeutic use of products 5.4.5
Myozyme 0.1 5.5 5.5 Analysis

6 MPS 5.6 Pipeline VI World Disease Therapeutics Market
market 6.1 Overview 6.2

average market forecast of 6.3 Cost of therapy
6.4 usage patterns

6.4.2 6.4.1 of sick of people being treated for

Diagnostic 6.4.3 Population 6.4.4 Population 6.4.5
habits prescription of therapeutic use
Analysis Product 6.5 6.5.1

Naglazyme 7 The United States Orphan Disease Therapeutics Market
market 7.1 Overview 7.2

market forecasts 7.3 usage patterns
7.3. a sick population
7.3.2 of the population seeks treatment
7.3.3 Population Population Diagnostics 7.3.4

7.3.5 Trends in the therapeutic use of prescription />
market 8.1 Overview 8.2

8.3 Market Forecasts usage patterns

8.3.1 Population 8.3.2
patient population seeking treatment population Diagnostics 8.3.3 8.3.4 8.3.5

population prescribing habits therapeutic
9 Japan Orpahn Disease Therapeutics Market
Market Overview 9.1 9.2

market forecasts 9.3 usage patterns

9.3.2 9.3.1 of sick people seeking treatment ” br />
Diagnostic 9.3.3 Population 9.3.4 Population 9.3.5 recipe

patterns of use of 10 therapeutic orphan disease world Therapeutics Market: Competitive Landscape

10.1 Introduction 10.2 Profile of competition
10.2.1 10.2.2 Genzyme Corporation Celgene Corporation

10.2.3 10.2.4 Actelion Pharmaceuticals Shire Pharmaceuticals

AstraZeneca 10.2.5 10.2.6 10.2.7
Boehringer Ingelheim, Bristol-Myers Squibb
10.2.8 GlaxoSmithKline (GSK), Novartis 10.2.9


02/10/10 02/10/11 10/02/12 Pfizer Eli Lilly Sanofi Aventis

02/10/13 10/02/14 UCB Pharma Wyeth
Pipeline Analysis 11 11.1

pirfenidone Rituxan 11 genetic disorders, 2
11.2. Inhalation solution Denufosol tetrasodium (INS37217)
11.2.2 Bronchitol (mannitol)
11.2.3 Catena (idebenone)

11.3 11.3.1 Infectious Diseases XP-28 (xepol)

Neurology 11.4.1 11.4.2 11.4 Cladribine Clazosentan
(Pivlaz ®) 11.5 Respiratory

11.6 Disorders Cardiovascular Transplantation 301 012 11.7 11.7.1
ISIS (sodium Mipomersen)

cancer Avastin 11.8 11.8.1 11.8.2 11.8.3

enzastaurin 8.11 4 patupilone Zactima

11.8.5 11.8.6 Genasense ipilimumab (MDX-010, MDX-101) 11.9

cancer blood cancer 10.11 11.11

12 other global orphan Therapeutics Market: Consolidation
12.1 Strategic Mergers and Acquisitions
Genzyme Corp. and Bioenvision 12.1 .1, and ViroPharma Inc.
Lev Pharmaceuticals
12.1.2 12.1.3 Biovitrum, Swedish Orphan
12.1.4 Shire plc and Zymenex A / s

12 License , 2 12.2.1 Overview 12.2.2
drug discovery and preclinical phase I

12.2.3 12.2.4 12.2.5 Phase I Phase III

13 Annex 12.2.6 Approved

13.1 13.2 Market data definitions abbreviations key support

Research Methodology 13.3 13.4

13.4.2 Coverage 13.4.1 Secondary Research 13.4.3
Primary Research 13.4.4 Forecasts

13.5 Expert Panel Validation 13.6 Contact

13.7 Waiver

For more information on this report and buy a copy please visit:
Contact:

Visionshopsters
Tel: 91-22-40583000
Email: Website marketing@visionshopsters.com
: www.visionshopsters.com

The industry analysis specialist’s new report on the pharmaceutical and healthcare sector, “Type 2 Diabetes – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global type 2 diabetes market. The report identifies the key trends shaping and driving the global type 2 diabetes market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global type 2 diabetes sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. ScopeThe scope of the report includes: – Annualized global type-2 diabetes therapeutics market revenues data from 2001 to 2009, forecast forward for 7 years to 2016. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. Key classes of mechanisms of action include SGLT-2 inhibitors, 11â HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis Inhibitors, interleukin-1â antagonists, gastrin-releasing peptide (GRP) receptor agonists, GPR 119 agonists,TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptor. – Analysis of the current and future market competition in the global type-2 diabetes therapeutics market. Key future market players covered are Hoffmann-La Roche, Novo Nordisk, Merck & Co. , Novartis Ag, Sanofi-aventis, Eli Lilly & Company and GlaxoSmithKline. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type-2 diabetes market. More Information Please Click:http://www. aarkstore. com/reports/Type-2-Diabetes-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40631. htmlOr Call Us: 919272852585Visit Our Blog: http://blogs. aarkstore. com

The industry analysis specialist, has released a new report on the Pharmaceutical and Healthcare industry, “Type 1 Diabetes – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global type 1 diabetes market. The report identifies the key trends shaping and driving the global type 1 diabetes market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global type 1 diabetes sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. ScopeThe scope of the report includes: Annualized global type 1 diabetes market revenues data from 2000 to 2009, forecast forward for 7 years to 2016. Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Analysis of the current and future market competition in the global type 1 diabetes market. Key market players include Novo Nordsik, Eli Lilly, GlaxoSmithKline and Sanofi-aventis. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type 1 diabetes. More Information Please Click:http://www. aarkstore. com/reports/Type-1-Diabetes-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40542. htmlOr Call Us: 919272852585Visit Our Blog: http://blogs. aarkstore. comKeywords: Diabetes, Drug, Type 1 Diabetes, Pipeline Analysis, Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies,  strategic competitor assessment, market characterization,  implications for future market, mechanism of action.

It is the industry analysis specialist’s new report, “Anti-Hypertension – Drug Pipeline Analysis and Market Forecasts to 2016″” is an essential source of information and analysis on the global anti-hypertension market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global anti-hypertension market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global anti-hypertension sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by  its team of industry experts. Scope The scope of the report includes: – Annualized global anti-hypertension market revenues data from 2001 to 2009, forecast forward for seven years to 2016. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class drugs act through new mechanisms of action such as eNOS (Endothelial Nitric Oxide Synthase) couplers, sodium-glucose transport 2 (SGLT2) inhibitors, endothelin antagonists, peroxisome proliferator-activated receptor (PPAR)-gamma agonists and cyclooxygenase-1 (COX-1) inhibitors. – Analysis of the current and future market competition in the global anti-hypertension market. Key future market-players covered are Novartis Ag, Merck & Co. Inc. , AstraZeneca, Takeda Pharmaceuticals, Daiichi Sankyo Co. Ltd, GlaxoSmithKline Plc, and Sanofi-Aventis. – Insightful reviews of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with anti-hypertension. For More Information Please Click:http://www. aarkstore. com/reports/Anti-hypertension-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-37973. html Or Call Us: 919272852585 Visit Our Blog: http://blogs. aarkstore. com

GlobalData forecasts the global candidiasis market to grow at 5. 9% annually for the next seven years to reach $2,386m by 2016. It was valued at $1,592m in 2009. This moderate growth will primarily be supported by an increase in the disease incidence rate and the launch of two promising pipeline molecules during the forecast period. The growth of the candidiasis market during the forecast period will not be much higher than the rate at which it grew between 2001 and 2009. This is primarily attributed to two reasons. First, the candidiasis market is dominated by generic products which generate less revenue per unit volume sold. Second, the pipeline of the candidiasis market is weak with a small number of molecules across different stages of development. But, the continued uptake of the currently marketed products and the launch of some of the late-stage pipeline molecules will sustain market growth during the forecast period.

For more information please click or add the below link to your browser:

http://www. globaldata. com/reportstore/Report. aspx?ID=Candidiasis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

GlobalData’s analysis has found that the current competition in the candidiasis market is strong. The current candidiasis market landscape has more than 10 marketed products. The marketed products fall under three different classes: azoles, polyenes and echinocandins. Polyenes and azoles are some of the oldest classes of drugs being used in the treatment of different types of Candida infection. The drugs from these classes are quite successful in meeting the therapeutic needs of the market and have first rate efficacy and safety profiles. Moreover, these drugs are available in different dosage forms and have high patient compliance rates. Echinocandins are available in an intravenous dosage form and have medium to high efficacy in the treatment of serious Candida infections such as invasive candidiasis, esophageal candidiasis and systemic candidiasis. Furthermore, all the products are able to cure the Candida infection in most of the cases. Because the current treatment options offer high clinical and safety standards and successfully meet the market demands, the unmet need in the candidiasis market is low.

GlobalData, the industry analysis specialist, has released its latest report, “Candidiasis – Drug Pipeline Analysis and Market Forecasts to 2016″, which provides the key data, information and analysis on the candidiasis market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with candidiasis, a competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for the future market competition, and the key players in the candidiasis market.

Visit our report store: http://www. globaldata. com/reportstore

GlobalData’s report, “Nonalcoholic Steatohepatitis (NASH)– Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global nonalcoholic steatohepatitis market. The report identifies the key trends shaping and driving the global nonalcoholic steatohepatitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global nonalcoholic steatohepatitis sector. GlobalData estimated that the Nonalcoholic Steatohepatitis (NASH) market was worth $1. 8 billion in 2009. The major reason for the limited market revenues is that there is no approved drug for the treatment of NASH. NASH is an unrecognized cause of cryptogenic cirrhosis with emerging importance. It is a more aggressive form of NAFLD (Nonalcoholic Fatty Liver Disease), which often progresses to liver cirrhosis. The increased prevalence of diabetes, obesity and hyperlipidemia are considered to be vital causes of NASH. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyperlipidemics are some of the off-mark products currently used by NASH patients. The modest growth forecast is primarily attributed to a weak pipeline landscape. Due to the fact that low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for prospective market entrants, the market landscape in future is expected to remain static without any significant dynamism.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes: – Annualized global nonalcoholic steatohepatitis market revenue data from 2001 to 2009, forecast for seven years to 2016. – Key geographies covered in this report include the US (the United States), the UK (the United Kingdom), Italy, Spain, Germany, France and Japan. – Pipeline analysis data providing a split across the different phases of development by mechanism of action and emerging trends. The key classes of mechanism of action include dietary supplements, enzyme inhibitors, PPAR (peroxisome proliferator-activated receptor) gamma selective agonists, combination therapies, cholesterol Inhibitors, CB-1 cannabinoid receptor antagonists, angiotensin II receptor antagonists, lipid peroxidation inhibitors, glutathione enhancers and immunologic drugs. – Analysis of the current and future market competition in the global nonalcoholic steatohepatitis market. Key market players covered are Raptor Pharmaceuticals, Gilead Sciences, Axcan Pharma, Eli Lilly & Company and Enzo Biochem. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with NASH.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipelines. – Develop business strategies by understanding the trends shaping and driving the global NASH market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global NASH market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and make effective counter-strategies to gain a competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global NASH market landscape? – identify, know and capitalize.

TABLE OF CONTENTS

1 Table of contents 3 1. 1 List of Tables 5 1. 2 List of Figures 5

2 Nonalcoholic Steatohepatitis Market : Market Characterization 6 2. 1 Disease Overview 6 2. 2 Symptoms 7 2. 3 Diagnosis 7 2. 3. 1 Ultrasonography 7 2. 3. 2 Computed Tomography 8 2. 3. 3 Magnetic Resonance Imaging 8 2. 3. 4 Liver function tests 8 2. 3. 5 Liver Biopsy 8 2. 4 Treatment 8 2. 5 Epidemiology 9 2. 6 Prevention 10 2. 7 Nonalcoholic Steatohepatitis Disease Market Size 11 2. 8 Nonalcoholic Steatohepatitis Market Forecast and CAGR 12 2. 9 Drivers and Barriers for the Nonalcoholic Steatohepatitis Disease Market 13 2. 9. 1 Drivers for the NASH Market 13 2. 9. 2 Barriers for the NASH Market 14 2. 10 Opportunity and Unmet Need 15 2. 11 Key Takeaway 16

3 Nonalcoholic Steatohepatitis Market : Competitive Assessment 17 3. 1 Overview 17 3. 2 Strategic Competitor Assessment 17 3. 3 Product Profile for the Major Off-Mark Marketed Products in the Nonalcoholic Steatohepatitis Market 18 3. 3. 1 Antioxidants 18 3. 3. 2 Anti-diabetic Medications 19 3. 3. 3 Anti-obesity Medications 19 3. 3. 4 Antifibrotic Medications 19 3. 4 Key Takeaway 20

4 Nonalcoholic Steatohepatitis Market : Pipeline Assessment 21 4. 1 Overview 21 4. 2 Strategic Pipeline Assessment 21 4. 2. 1 Technology Trends Analytic Framework 21 4. 3 Nonalcoholic Steatohepatitis Therapeutics – Promising Drugs under Clinical Development 23 4. 4 Molecule Profile for Promising Drugs under Clinical Development 25 4. 4. 1 DR Cysteamine (delayed release cysteamine bitartrate) 25 4. 4. 2 GS 9450 (LB84451) 26 4. 4. 3 High-Dose Ursodesoxycholic acid (HD-UDCA) 27 4. 4. 4 Byetta (exenatide) 27 4. 4. 5 EGS21 (beta glucosylceramide formulation) 28 4. 5 Nonalcoholic Steatohepatitis Market – Clinical Pipeline by Mechanism of Action 30 4. 6 Nonalcoholic Steatohepatitis – Pipeline by Clinical Phases of Development 30 4. 6. 1 Nonalcoholic Steatohepatitis Therapeutics – Phase III Clinical Pipeline 31 4. 6. 2 Nonalcoholic Steatohepatitis Therapeutics – Phase II Clinical Pipeline 31 4. 6. 3 Nonalcoholic Steatohepatitis Therapeutics – Phase I Pipeline 32 4. 6. 4 Nonalcoholic Steatohepatitis Therapeutics – Preclinical Pipeline 32 4. 7 Discontinued Drug for Nonalcoholic Steatohepatitis Disease 32 4. 8 Key Takeaway 33

5 Nonalcoholic Steatohepatitis Market : Implications for Future Market Competition 34

6 Nonalcoholic Steatohepatitis Disease Market : Future Players in the Nonalcoholic Steatohepatitis Market 36 6. 1 Introduction 36 6. 2 Raptor Pharmaceuticals 36 6. 2. 1 Company Overview 36 6. 2. 2 Gastroenterology Disease Portfolio 37 6. 2. 3 Nonalcoholic Steatohepatitis Product Portfolio 37 6. 3 Gilead Sciences 38 6. 3. 1 Company Overview 38 6. 3. 2 Gastroenterology Disease Portfolio 39 6. 3. 3 Nonalcoholic Steatohepatitis Product Portfolio 39 6. 3. 4 Axcan Pharma 40 6. 3. 5 Company Overview 40 6. 3. 6 Gastroenterology Portfolio 41 6. 3. 7 Nonalcoholic Steatohepatitis Product Portfolio 42 6. 4 Eli Lilly and Company 43 6. 4. 1 Company Overview 43 6. 4. 2 Gastroenterology Portfolio 43 6. 4. 3 Nonalcoholic Steatohepatitis Product Portfolio 43 6. 5 Enzo Biochem 44 6. 5. 1 Company Overview 44 6. 5. 2 Gastroenterology Portfolio 46 6. 5. 3 Nonalcoholic Steatohepatitis Product Portfolio 46

7 Nonalcoholic Steatohepatitis Market : Appendix 48 7. 1 Market Definitions 48 7. 2 Abbreviations 48 7. 3 Research Methodology 49 7. 3. 1 Coverage 50 7. 3. 2 Secondary Research 50 7. 3. 3 Forecasting 50 7. 3. 4 Primary Research 53 7. 3. 5 Expert Panels 53 7. 4 Contact Us 53 7. 5 Disclaimer 53 7. 6 Sources 54

Pharmaceutical report offering, “Anemia – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global anemia market. The report identifies the key trends shaping and driving the global anemia market. The report also provides insight into the competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global anemia market. Valued the anemia market in 2009 at $10. 4 billion, indicating a Compound Annula Growth Rate (CAGR) of 8. 5% between 2001 and 2009. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. Evaluated the current competition in the anemia market as weak. Though iron deficiency anemia accounts for 40% of the total anemia population, none of the drugs indicated for iron deficiency anemia became a blockbuster. But, the majority of the ESAs that are indicated for selected types of anemia are blockbusters and currently dominate the market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Scope

The scope of the report includes:

- Annualized global anemia market revenues data from 2001 to 2009, forecast forward for seven years to 2016.

- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class molecules are primarily Oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, transforming growth factor (TGF)-beta inhibitors and transferrin receptor (TfR) targetters.

- Analysis of the current and future market competition in the global anemia market. Key future market players covered are Affymax, Pharmacosmos, Amgen Inc. , Hoffmann-La Roche, Chugai – Pharmaceutical Celgene Corporation, Hoffmann-La Roche, and Johnson and Johnson.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with the anemia market. For More Information Please Click:http://www. aarkstore. com/reports/Anemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-43090. html

Or Call Us: 919272852585

Visit Our Blog: http://blogs. aarkstore. com

The industry analysis specialist’s new report, “Irritable Bowel Syndrome – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global irritable bowel syndrome market. The report identifies the key trends shaping and driving the global irritable bowel syndrome market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global irritable bowel syndrome sector.   This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.   Scope  The report provides information on the key driver and challenges of the global irritable bowel syndrome market. Its scope includes:  - Annualized global irritable bowel syndrome market revenues data from 2000 to 2009, forecast for seven years to 2016.  - Key geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.  - Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include guanylate cyclase type C receptor agonists, serotonin receptors targets, corticotrophin releasing factor 1 receptor antagonists, NK receptor targets and 5-aminosalicylate targets.  - Analysis of the current and future market competition in the global irritable bowel syndrome market. Key market players covered include Sucampo Pharmaceuticals, Tillotts Pharma AG, GSK, Axcan Pharma, Salix Pharmaceuticals and Tioga Pharmaceuticals.  - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.  - Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future irritable bowel syndrome market.   Reasons to buy  The report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to: - Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.  - Develop business strategies by understanding the trends shaping and driving the global irritable bowel syndrome market.  - Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global irritable bowel syndrome market in future.  - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.  - Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.  - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.  - What’s the next huge thing in the global irritable bowel syndrome market landscape? – Identify, know and capitalize.

For more information, please contact :

http://www. aarkstore. com/reports/Irritable-Bowel-Syndrome-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40308. html

Pharmaceutical and healthcare report, “Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016″. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector.  This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData’s analysis suggests that the global hemophilia market was valued at $6. 5 billion in 2009. This slow growth is primarily attributed to a low diagnosis rate and the high price of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX from Baxter Laboratories. BeneFIX is a clotting factor IX.  ScopeThe scope of the report includes:

Annualized global hemophilia market revenues data from 2001 to 2009, forecast for seven years to 2016.

Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.

Pipeline analysis data providing a split across different phases by the mechanism of action being developed and the emerging trends. The key classes of mechanism of action include substitution of coagulation factor VIII, increasing clotting factor VIII, plasma-derived FVIII.

Analysis of the current and future market competition in the global hemophilia market. The key market players covered are PTC Therapeutics, Recoly N. V. , Novo Nordisk.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia market.

Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global haemophilia market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global haemophilia market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next huge thing in the global haemophilia market landscape? – Identify, know and capitalize

For more information on the report, kindly visit : http://www. visionshopsters. com/product/3183/Hemophilia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016. html———————————————-

The industry analysis specialist, has released a new report, “Ovarian Cancer – Drug Pipeline Analysis and Market Forecasts to 2016″. The report is an essential source of information and analysis on the global ovarian cancer market. The report identifies the key trends shaping and driving the global ovarian cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ovarian cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. Estimated the global ovarian cancer market to be valued at $697 million in 2009. It is forecast to grow by 13. 1% annually for the next seven years to reach $1,650 million by 2016. This growth is primarily attributed to high prescription rate of existing chemotherapy, strong pipeline and advancement of new targeted therapies. Analyzed that the global ovarian cancer market is moderately served with current product options and significant scope available to new entrants that would capture value from underserved segments. Designing curable products with high efficacy and safety profile is one of key challenges of this market and could provide significant market share for any company.   Analyzed that the global ovarian cancer market is increasingly becoming more competitive. Balancing the pipeline with the current marketed products and expectations of patients and physicians, the pipeline is considered to be strong. The unmet need in ovarian cancer market is high and if a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects. ScopeAnnualized global ovarian cancer market revenues data from 2001 to 2009, forecast forward 7 years to 2016. Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes topoisomerase inhibitor, drugs targeting DNA, vaccines, drugs targeting growth factor and growth factor receptors, folate receptor binder, kinase inhibitor, drugs targeting cytokines and combinations therapy. Analysis of the current and future market competition in the global ovarian cancer market. Key market players covered are F. Hoffmann-La Roche Ltd/Genentech, Inc. , Menarini Group, Novartis AG, Cell Therapeutics Inc. , Telik, Inc. and BioNumerik Pharmaceuticals Inc. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with ovarian cancer. For More Information Please Click :http://www. aarkstore. com/reports/Ovarian-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40533. html

The industry analysis specialist, has released a new report on the Pharmaceutical and Healthcare industry, “Angina Pectoris – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global angina pectoris market. The report identifies the key trends shaping and driving the global angina pectoris market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global angina pectoris sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. ScopeThe scope of the report includes: – Annualized global angina pectoris market revenue data from 2001 to 2009, forecast forward 7 years to 2016. – Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action includes gene therapy, combinational therapies, nitric oxide targettors, beta-1 adrenergic receptor antagonists, stem cell therapy, enzyme inhibitors, immunologic drugs, coagulation factor Xa inhibitors, adenosine A1 agonists, anticoagulants and calcium/potassium and sodium channel blockers. – Analysis of the current and future market competition in the global angina pectoris market. The key market players covered are Solvay Pharmaceuticals, Cardium Therapeutics, Inc. , Bayer Healthcare AG. , Atherogenics, Inc. , Cytokinetics, Inc, Arca Biopharma, Inc. , Anthera Pharmaceuticals, Inc, Lacer S. A and Circ Pharma. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with angina pectorisReasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global angina pectoris market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global angina pectoris market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global angina pectoris market landscape? – Identify, know and capitalize. ” $2,000 $4,000 $6,000 GDHCPRT025 Pharmaceuticals and Healthcare Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action.   

For more information,please visit:

http://www. aarkstore. com/reports/Angina-Pectoris-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40605. html

The industry analysis specialist’s new report on the pharmaceutical and healthcare sector, “Type 2 Diabetes – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global type 2 diabetes market. The report identifies the key trends shaping and driving the global type 2 diabetes market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global type 2 diabetes sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. ScopeThe scope of the report includes: – Annualized global type-2 diabetes therapeutics market revenues data from 2001 to 2009, forecast forward for 7 years to 2016. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. Key classes of mechanisms of action include SGLT-2 inhibitors, 11â HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis Inhibitors, interleukin-1â antagonists, gastrin-releasing peptide (GRP) receptor agonists, GPR 119 agonists,TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptor. – Analysis of the current and future market competition in the global type-2 diabetes therapeutics market. Key future market players covered are Hoffmann-La Roche, Novo Nordisk, Merck & Co. , Novartis Ag, Sanofi-aventis, Eli Lilly & Company and GlaxoSmithKline. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type-2 diabetes market. Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global type 2 diabetes market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global type 2 diabetes market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global type 2 diabetes market landscape? – Identify, know and capitalize. ” $2,000 $4,000 $6,000 GDHCPRT039 Pharmaceuticals and Healthcare Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action.   

For more information,please visit:

http://www. aarkstore. com/reports/Type-2-Diabetes-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40631. html

The industry analysis specialist’s new report on the pharmaceutical and healthcare sector, “Anti-Obesity – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global anti-obesity market. The report identifies the key trends shaping and driving the global anti- obesity market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global anti-obesity sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. ScopeThe scope of the report includes: – Annualized global anti-obesity market revenues data from 2001 to 2009, forecast forward for seven years to 2016. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed, and emerging trends. The pipeline candidates fall under the major categories such as appetite suppressants, calorie/stout absorption inhibitors, metabolism boosters and combination drugs. – Analysis of the current and future market competition in the global anti-obesity market. Key future market players covered are Orexigen Therapeutics, Arena Pharmaceuticals, and Vivus, Inc. which holds some of the most promising molecules that have demonstrated greater efficacy or safety or both. In addition, companies such as Alizyme Therapeutics, and NeuroSearch A/S are found to be the companies with noticeable Phase III molecules. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with anti-obesity. Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global anti-obesity market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global anti-obesity market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global anti-obesity market landscape? – Identify, know and capitalize. ” $2,000 $4,000 $6,000 GDHCPRT041 Pharmaceuticals and Healthcare Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action.

For more information,please visit:

http://www. aarkstore. com/reports/Anti-Obesity-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40635. html

Nonalcoholic Steatohepatitis (NASH)– Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global nonalcoholic steatohepatitis market. The report identifies the key trends shaping and driving the global nonalcoholic steatohepatitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global nonalcoholic steatohepatitis sector. GlobalData estimated that the Nonalcoholic Steatohepatitis (NASH) market was worth $1. 8 billion in 2009. The major reason for the limited market revenues is that there is no approved drug for the treatment of NASH. NASH is an unrecognized cause of cryptogenic cirrhosis with emerging importance. It is a more aggressive form of NAFLD (Nonalcoholic Fatty Liver Disease), which often progresses to liver cirrhosis. The increased prevalence of diabetes, obesity and hyperlipidemia are considered to be vital causes of NASH. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyperlipidemics are some of the off-mark products currently used by NASH patients. The modest growth forecast is primarily attributed to a weak pipeline landscape. Due to the fact that low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for prospective market entrants, the market landscape in future is expected to remain static without any significant dynamism. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by  team of industry experts. ScopeThe scope of the report includes: – Annualized global nonalcoholic steatohepatitis market revenue data from 2001 to 2009, forecast for seven years to 2016. – Key geographies covered in this report include the US (the United States), the UK (the United Kingdom), Italy, Spain, Germany, France and Japan. – Pipeline analysis data providing a split across the different phases of development by mechanism of action and emerging trends. The key classes of mechanism of action include dietary supplements, enzyme inhibitors, PPAR (peroxisome proliferator-activated receptor) gamma selective agonists, combination therapies, cholesterol Inhibitors, CB-1 cannabinoid receptor antagonists, angiotensin II receptor antagonists, lipid peroxidation inhibitors, glutathione enhancers and immunologic drugs. – Analysis of the current and future market competition in the global nonalcoholic steatohepatitis market. Key market players covered are Raptor Pharmaceuticals, Gilead Sciences, Axcan Pharma, Eli Lilly & Company and Enzo Biochem. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with NASH. Reasons to buy- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipelines. – Develop business strategies by understanding the trends shaping and driving the global NASH market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global NASH market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and make effective counter-strategies to gain a competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global NASH market landscape? – identify, know and capitalize. “ 

For more information, please contact :

http://www. aarkstore. com/reports/Nonalcoholic-Steatohepatitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40850. html 

Pharmaceutical and healthcare report,” Allergic Conjunctivitis – Drug Pipeline Analysis and Market Forecasts to 2016″ provides essential source of information and analysis on the global allergic conjunctivitis market. The report identifies the key trends shaping and driving the global allergic conjunctivitis market. The report also provides insights into the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights into the pipeline products within the global allergic conjunctivitis sector.  This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData estimated the allergic conjunctivitis market in 2009 to be $1,069m. Allergic conjunctivitis is the most common type of eye allergy and is widely experienced by the global population. The incidence appears to be on the increase, possibly due to air pollution and allergens worldwide. The global allergic conjunctivitis market in 2009 primarily comprised of drug classes which included anti-histamines, mast cell stabilizers, dual action agents, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid products. The current allergic conjunctivitis market is dominated by brands, generics and off-mark formulations which have high patient affordability, and there is strong competition. The pipeline for allergic conjunctivitis lacks innovation and has 17 molecules in clinical development. Allergic conjunctivitis market has low unmet needs as the market is well served by the currently available different treatment options from different classes of therapiesScopeThe scope of the report includes:

Annualized global allergic conjunctivitis market revenues data from 2001 to 2009, forecast for seven years to 2016.

Geographies covered in this report are the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.

Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include antihistamines/anti-allergic drugs which account for the largest share of the pipeline fallowed by immunosuppressants, NSAIDs, immunotherapy and PDE4 (Phosphodiesterase type 4) inhibitors.

Analysis of the current and future market competition in the global allergic conjunctivitis market. The key market players covered are Novagali Pharma SA, Fovea Pharmaceuticals SA, Cytos Biotechnology AG and Ono Pharmaceutical Co. Ltd.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future allergic conjunctivitis market.

Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global allergic conjunctivitis market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global allergic conjunctivitis market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next huge thing in the global allergic conjunctivitis market landscape? – Identify, know and capitalize.

For more information on the report, kindly visit : http://www. visionshopsters. com/product/3184/Allergic-Conjunctivitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016. html———————————————-

WorldMarketStudy announces it Will Carry GlobalData’s Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016 June reports in its store. Browse complete report at http://www. worldmarketstudy. com/market-report/hemophilia-drug-pipeline-analysis-market-forecasts-2016-500. html GlobalData’s pharmaceutical and healthcare report, “Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016″. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData’s analysis suggests that the global hemophilia market was valued at $6. 5 billion in 2009. This slow growth is primarily attributed to a low diagnosis rate and the high price of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX from Baxter Laboratories. BeneFIX is a clotting factor IX. ScopeThe scope of the report includes:Annualized global hemophilia market revenues data from 2001 to 2009, forecast for seven years to 2016. Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.  Pipeline analysis data providing a split across different phases by the mechanism of action being developed and the emerging trends. The key classes of mechanism of action include substitution of coagulation factor VIII, increasing clotting factor VIII, plasma-derived FVIII. Analysis of the current and future market competition in the global hemophilia market. The key market players covered are PTC Therapeutics, Recoly N. V. , Novo Nordisk. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia market. Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global haemophilia market. Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global haemophilia market in future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. What’s the next huge thing in the global haemophilia market landscape? – Identify, know and capitalize1 Table of contents 1. 1 List of Tables 1. 2 List of Figures 2 Hemophilia Market: Market Characterization 2. 1 Overview 2. 2 Hemophilia Therapeutics Market Size 2. 3 Hemophilia Therapeutics Market Forecast and CAGR 2. 4 Drivers and Barriers for the Hemophilia Therapeutics Market 2. 4. 1 Drivers for the Hemophilia Therapeutics Market 2. 4. 2 Barriers for the Hemophilia Therapeutics Market 2. 5 Opportunity and Unmet Need 2. 6 Key Takeaway 3 Hemophilia Therapeutics Market: Competitive Assessment 3. 1 Overview 3. 2 Strategic Competitor Assessment 3. 3 Product Profile for the Major Marketed Products in the Hemophilia Therapeutics Market 3. 3. 1 NovoSeven 3. 3. 2 Kogenate FS 3. 3. 3 Xyntha 3. 3. 4 Advate 3. 4 Key Takeaway 4 Hemophilia Therapeutics Market: Pipeline Assessment 4. 1 Overview 4. 2 Strategic Pipeline Assessment 4. 2. 1 Technology Trends Analytic Framework 4. 3 Hemophilia Therapeutics – Promising Drugs under Clinical Development 4. 4 Molecule Profile for Promising Drugs under Clinical Development 4. 4. 1 Ataluren (PTC124) 4. 4. 2 NecLip-rFVIIa (LongSeven) 4. 4. 3 rFVIII (Recombinant factor VIIa (N8)) 4. 5 Hemophilia Therapeutics Market – Clinical Pipeline by Mechanism of Action 4. 6 Hemophilia Therapeutics Pipeline – Pipeline by Clinical Phase of Development 4. 6. 1 Hemophilia Therapeutics – Phase III Clinical Pipeline 4. 6. 2 Hemophilia Therapeutics – Phase II Clinical Pipeline 4. 6. 3 Hemophilia Therapeutics – Phase I Clinical Pipeline 4. 6. 4 Hemophilia Therapeutics – Pre-clinical Pipeline 4. 7 Key Takeaway 5 Hemophilia Therapeutics Market: Implications for Future Market Competition 6 Hemophilia Therapeutics Market: Future Players in the Hemophilia Therapeutics Market 6. 1 Introduction 6. 2 PTC Therapeutics 6. 2. 1 Overview 6. 2. 2 Hemophilia Portfolio 6. 2. 3 Hemophilia Pipeline Portfolio 6. 2. 4 Ataluren (PTC124) 6. 3 Recoly N. V. 6. 3. 1 Overview 6. 3. 2 Hemophilia Portfolio 6. 3. 3 Hemophilia Pipeline Portfolio 6. 3. 4 NecLip-rFVIIa (LongSeven) 6. 4 Novo Nordisk 6. 4. 1 Overview 6. 4. 2 Hemophilia Portfolio 6. 4. 3 Hemophilia Pipeline Portfolio 6. 4. 4 rFVIII (Recombinant factor VIIa (N8)) 7 Hemophilia Therapeutics Market: Appendix 7. 1 Definitions 7. 2 Acronyms 7. 3 Research Methodology 7. 3. 1 Coverage 7. 3. 2 Secondary Research 7. 3. 3 Forecasting 7. 3. 4 Primary Research 7. 3. 5 Expert Panel Validation 7. 4 Contact Us 7. 5 Disclaimer 7. 6 Sources 1. 1 List of TablesTable 1: Hemophilia Therapeutics Market, Global, Revenues ($bn), 2001-2009 Table 2: Hemophilia Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016Table 3: Major Marketed Products Comparison in the Hemophilia Therapeutics Market, 2010 Table 4: Hemophilia Therapeutics – Most Promising Drugs Under Clinical Development, 2010 Table 5: Hemophilia Therapeutics – Phase III Clinical Pipeline, 2010 Table 6: Hemophilia Therapeutics – Phase II Clinical Pipeline, 2010 Table 7: Hemophilia Therapeutics – Phase I Clinical Pipeline, 2010 Table 8: Hemophilia Therapeutics – Pre-Clinical Pipeline,  2010 Table 9: PTC Therapeutics, Inc. – Hemophilia Pipeline Products, 2010 Table 10: Recoly N. V. – Hemophilia Pipeline Products, 2010 Table 11: Novo Nordisk – Hemophilia Pipeline Products, 20101. 2 List of FiguresFigure 1: Hemophilia Therapeutics Market, Global, Revenues ($bn), 2001-2009 Figure 2: Hemophilia Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016 Figure 3: Opportunity and Unmet Need in the Hemophilia Therapeutics Market, 2010 Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Hemophilia Therapeutics, 2010 Figure 5: Technology Trends Analytic Framework of the Hemophilia Pipeline, 2010 Figure 6: Technology Trends Analytic Framework of the Hemophilia Therapeutics  Pipeline – Description, 2010 Figure 7: Hemophilia Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action (%), 2010 Figure 8: Hemophilia Therapeutics Pipeline by Phase of Clinical Development, 2010 Figure 9: Implications for Future Market Competition in the Hemophilia Therapeutics Market,  2010 Figure 10:Hemophilia Therapeutics Market – Clinical Pipeline by Company (No. of Molecules), 2010 Figure 11:GlobalData Methodology, 2010 Figure 12:GlobalData Market Forecasting Model, 2010View All Pharmaceuticals Market Reports http://www. worldmarketstudy. com/Pharmaceuticals-market-research-4. html

WorldMarketStudy announces it Will Carry GlobalData’s Pneumonia – Drug Pipeline Analysis and Market Forecasts to 2016 June reports in its store.

 

Browse complete report at http://www. worldmarketstudy. com/market-report/pneumonia-drug-pipeline-analysis-market-forecasts-2016-501. html

GlobalData’s pharmaceutical and healthcare report offering, “Pneumonia – Drug Pipeline Analysis and Market Forecasts to 2016″. is an essential source of information and analysis on the global pneumonia market. The report identifies the key trends shaping and driving the global pneumonia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumonia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData’s analysis suggests that the global pneumonia market was worth $1. 4 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 4. 3% for the next seven years to reach $1 billion by 2016. The projected decline rate is primarily attributable to the patent expiries of Levaquin, Avelox and Zyvox by the end of the forecast period. Increases in the treatment seeking population, the diagnosis population and the ever-increasing development of bacterial resistance to marketed antibiotics are expected to sustain the pneumonia market. Scope The scope of the report includes:

Reasons to buy The report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

1 Table of Contents 1. 1 List of Tables 1. 2 List of Figures

2 Pnemonia Therapeutics Market: Market Characterization 2. 1 Overview 2. 2 Pneumonia Therapeutics Market Size 2. 3 Pneumonia Therapeutics Market Forecast and CAGR 2. 4 Drivers and Barriers for the Pneumonia Therapeutics Market 2. 4. 1 Drivers for the Pneumonia Therapeutics Market 2. 4. 2 Barriers for the Pneumonia Therapeutics Market 2. 5 Opportunity and Unmet Need 2. 6 Key Takeaway

3 Pneumonia Therapeutics Market: Competitive Assessment 3. 1 Overview 3. 2 Strategic Competitor Assessment 3. 3 Product Portfolio for Major Marketed Products in the Pneumonia Therapeutics Market 3. 3. 1 Zyvox (linezolid) 3. 3. 2 Zosyn (piperacillin and tazobactam) 3. 3. 3 Levaquin (levofloxacin) 3. 3. 4 Avelox (moxifloxacin) 3. 3. 5 Omnicef (cefdinir) 3. 3. 6 Tygacil (tigecycline) 3. 3. 7 Doribax (doripenem) 3. 4 Key Takeaway

4 Pneumonia Therapeutics Market: Pipeline Assessment 4. 1 Overview 4. 2 Strategic Pipeline Assessment 4. 2. 1 Technology Trends Analytical Framework 4. 3 Pneumonia Therapeutics – Promising Drugs under Clinical Development 4. 4 Molecule Profiles for Promising Drugs under Clinical Development 4. 4. 1 Ceftaroline 4. 4. 2 Ceftobiprole medocaril 4. 4. 3 Restanza (cethromycin) 4. 4. 4 Vibativ (telavancin) 4. 5 Pneumonia Therapeutics Market – Pipeline Assessment by Mechanism of Action 4. 6 Pneumonia Therapeutics Market – Pipeline Assessment by Phase of Clinical Development 4. 6. 1 Pneumonia Therapeutics – Phase III Clinical Pipeline 4. 6. 2 Pneumonia Therapeutics – Phase II Clinical Pipeline 4. 6. 3 Pneumonia Therapeutics – Phase I Clinical Pipeline 4. 6. 4 Pneumonia Therapeutics – Preclinical Pipeline 4. 6. 5 Pneumonia Therapeutics – Discovery Pipeline 4. 7 Discontinued/Suspended Drugs for Pneumonia 4. 8 Key Takeaway

5 Pneumonia Therapeutics Market: Implications for Future Market Competition

6 Pneumonia Therapeutics Market: Future Players in the Pneumonia Therapeutics Market 6. 1 Forest Laboratories, Inc. 6. 1. 1 Company Overview 6. 1. 2 Ceftaroline 6. 2 Basilea Pharmaceutica 6. 2. 1 Company Overview 6. 2. 2 Ceftobiprole medocaril 6. 3 Advanced Life Sciences 6. 3. 1 Company Overview 6. 3. 2 Restanza (cethromycin) 6. 4 Theravance, Inc. 6. 4. 1 Company Overview 6. 4. 2 Vibativ (telavancin)

7 Pneumonia Therapeutics Market: Appendix 7. 1 Definitions 7. 2 Acronyms 7. 3 Research Methodology 7. 4 Coverage 7. 5 Secondary Research 7. 6 Primary Research 7. 7 Models 7. 8 Forecasts 7. 9 Expert Panels 7. 10 Sources 7. 11 GlobalData Consulting 7. 12 Contact Us 7. 13 Disclaimer1. 1 List of Tables Table 1: Empirical Antimicrobial Therapy for Pneumonia, 2010 Table 2: Pneumonia Therapeutics Market, Global, Revenues ($m), 2001-2009 Table 3: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 Table 4: Cure Rates of Zyvox in Nosocomial Pneumonia, 2010 Table 5: Cure Rates of Zyvox in Community-Bought Pneumonia due to MDRSP, 2010 Table 6: Pneumonia Therapeutics Market, Global, Most Promising Molecules under Clinical Development, May 2010 Table 7: Pneumonia Therapeutics Market, Global, Phase III Clinical Pipeline, 2010 Table 8: Pneumonia Therapeutics Market, Global, Phase II Clinical Pipeline, 2010 Table 9: Pneumonia Therapeutics Market, Global, Phase I Clinical Pipeline, 2010 Table 10: Pneumonia Therapeutics Market, Global, Preclinical Pipeline, 2010 Table 11: Pneumonia Therapeutics Market, Global, Discovery Pipeline, 2010 Table 12: Pneumonia Therapeutics Market, Global, List of Discontinued Drugs, 20101. 2 List of Figures Figure 1: Pneumonia Therapeutics Market, Global, Revenues ($m), 2001-2009 Figure 2: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 Figure 3: Pneumonia Therapeutics Market, Global, Opportunity and Unmet Need, 2010 Figure 4: Pneumonia Therapeutics Market, Global, Strategic Competitor Assessment of the Major Marketed Products, 2010 Figure 5: Pneumonia Therapeutics Pipeline, Global, Technology Trends Analytic Framework, 2010 Figure 6: Pneumonia Therapeutics Market, Global, Technology Trends Analytic Framework, Description—2010 Figure 7: Pneumonia Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action, 2010 Figure 8: Pneumonia Therapeutics Market, Global, Clinical Pipeline, 2010 Figure 9: Pneumonia Therapeutics Market, Global, Implications for Future Market Competition, 2010 Figure 10: Pneumonia Therapeutics Market, Global, Clinical Pipeline by Company, 2010 Figure 11: GlobalData Methodology, 2010

View All Pharmaceuticals Market Reports http://www. worldmarketstudy. com/Pharmaceuticals-market-research-4. html

The industry analysis specialist’s new report, “Alzheimer’s Disease – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global Alzheimer’s disease market. The report identifies the key trends shaping and driving the dynamism in the global Alzheimer’s disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Alzheimer’s disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by  team of industry experts. ScopeThe scope of the report includes:- Annualized global Alzheimer’s disease market revenues data from 2000 to 2008, forecast forward for 7 years to 2015. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include immunotherapy, NMDA agonists, acetylcholine inhibitors, gamma secretase modulators, serotonin receptor antagonists, muscarinic receptor agonists, alpha secretase enhancers, beta secretase inhibitors, tau inhibitors and non-steroidal anti-inflammatory classes of drugs. – Analysis of the current and future market competition in the global Alzheimer’s disease market. Each trend is independently researched to provide qualitative analysis of what the implications on sectors are, and how are companies responding to these trends. – Insightful review of the future market players, key industry drivers, restraints and challenges which are likely to impact the Alzheimer’s disease therapeutics market in the long run. Key future market players covered are Wyeth, Elan, Astrazeneca, Medivation and Baxter Healthcare. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with Alzheimer’s disease. Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global Alzheimer’s disease market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Alzheimer’s disease market in future. – L2Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global Alzheimer’s disease market landscape? – Identify, know and capitalize. ” $2,000 $4,000 $6,000 GDHCPRT005 Pharmaceuticals and Healthcare Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, immunotherapy, NMDA agonists, acetylcholine inhibitors, gamma secretase modulators, serotonin receptor antagonists, muscarinic receptor agonists, alpha secretase enhancers, beta secretase inhibitors, tau inhibitors and non-steroidal anti-inflammatory classes of drugs  

For more information,please visit:

http://www. aarkstore. com/reports/Alzheimer’s-Disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40570. html

 

The industry analysis specialist’s new report, “Psoriasis – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global psoriasis market. The report identifies the key trends shaping and driving the dynamism in the global psoriasis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global psoriasis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. Estimated the psoriasis market to be worth $2. 4 billion in 2008 with projected CAGR of 7. 3% and projected market value to exceed $4. 1 billion in 2015. The psoriasis disease market is forecast to show high growth. This growth will be driven or supported by the increased prescription rate and uptake of biologics, more emerging therapies and diverse treatment options that will be available for patients in the near future. Barriers for the psoriasis market exist in terms of low diagnosis rate. The psoriasis market has relatively high unmet need largely driven by the poor safety profile of existing products. Found that there are over 125 molecules in various stages of the pipeline. Voclosporin, ABT-874, CF-10 are some of the late stage pipeline molecules. Orencia, Cimzia, Apremilast and INCB18424 are some of the promising therapies in the Phase II stage of the pipeline. These pipeline molecules differ in their target of action from the existing therapies. Patient perception of disease severity drives treatment-seeking behavior in the psoriasis market. New therapeutic options targeting specific mechanisms are set to reshape the psoriasis therapy. But, the current biologics have not undermined first-line topical therapy and hence there exists intensified competition between the current therapeutics and the emerging therapies. The pipeline has seen an increase in the development of emerging therapies like biologics as they have the ability to change the natural course of the disease. Emerging therapies have gained a positive perception among physicians in the maintenance of remission. There is likely to be a tremendous increase in the prescription of biologics due to increased awareness and also promising safety and efficacy results of promising therapies. The emerging therapies are likely to crowd the market and there is the possibility of price war. Found that the current competition in the psoriasis market is becoming intense due to the increased entry of biologics. It projects that Immunex Corporation, Abbott laboratories. Biogen Idec and Centocor will remain the leading competitiors of the global psoriasis biologics market. Compared to other autoimmune disease markets, this market has witnessed a greater entry of biologics. Though only a small segment of people tend to use biologics, their launch has increased competition in the psoriasis disease market. Amgen and Wyeth’s Enbrel is the market leader in the psoriasis disease market. It is followed by Abbott’s Humira, Leo Pharma and Warner Chiclott’s Dovonex, Centocor’s Remicade, Genentech’s Raptiva, Novartis’s Neoral (generic), followed by Allergan’s Tazorac, Biogen Idec’s Fumaderm and Biogen Idec and Astellas Pharma’s Amevive. Scope of the ReportScope of the report includes:

Annualized global psoriasis market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include TNF-alpha inhibitors, interleukin inhibitors, vitamin D3 analogues, topical corticosteroids, enzyme inhibitors, immunomodulatory drugs, anti-inflammatory drugs, T cell modulators and ion channel modulators.

Analysis of the current and future market competition in the global psoriasis market. Each trend is independently researched to provide qualitative analysis of what the implications on sectors are, and how are companies responding to these trends.

Insightful review of the future market players, key industry drivers, restraints and challenges which are likely to impact the psoriasis therapeutics market in the long run. Key future market players covered are Isotechnika, Can-Fite Biopharma, UCB, Celgene Corporation, Incyte, Glaxosmithkline, Bristol-Myers Squibb, Leo Pharma, Novartis and Abbott Laboratories.

Key topics covered include promising drugs in the pipeline, strategic competitor assessment, market psoriasis.

Reasons to BuyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global psoriasis market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global psoriasis market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next huge thing in the global psoriasis market landscape? – Identify, know and capitalize.

For more information,please visit:

http://www. aarkstore. com/reports/Psoriasis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40536. html

The industry analysis specialist’s new report, “Neuropathic Pain – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neuropathic pain sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. Estimated the global neuropathic pain market to be valued at $4. 8 billion in 2008. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4. 3% from $4. 8 billion in 2008 to $6. 5 billion in 2015. This growth will be supported by the increase in the aging population, increased treatment seeking behavior, increased uptake of the current products. Diagnosis rate remains as one of the barriers for the growth of the market. The available treatment options are moderately successful in meeting the market demand. There is still a need for better therapy and there exists the unmet need. There exists a market potential for any new entrant that will cater these unmet needs. There is enormous opportunity for any drug that would offer better or retain the efficacy provided by the current players with increased safety than the current products. Analyzed that there are over 111 molecules in various stages of the pipeline. Vimpat, Qutenza, Fentora are some of the pipeline candidates in the regulatory filing stage for approval. The late stage pipeline includes some of the promising molecules like Ralfinamide, NP-1, Sativex. These drugs may retain the similar efficacy and offer better safety and may benefit the patient population who cannot endure the available drugs. The newer therapies may intensify the existing competition and there seems to be a possibility of price war. Scope of the ReportThe scope of the report includes:

Annualized global neuropathic pain market revenues data from 2006 to 2008, forecast forward for 7 years to 2015.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes opioid receptor agonists, cannabinoid receptor modulators, NMDA antagonists, protein kinase inhibitors, ion channel targetters, serotonin norepinephrine reuptake inhibitors, adenosine agonists, cytokine modulators, AMPA antagonists, nicotinic receptor agonists, TRPV1 receptor agonists, selective subtype sodium channel antagonists, iNOS/nNOS dual inhibitors.

Analysis of the current and future market competition in the global neuropathic pain market. Key future market players covered are NeurogesX, Cephalon Inc. , UCB S. A. , Newron Pharmaceuticals, EpiCept Corporation, GW Pharmaceuticals, Johnson & Johnson, Avanir pharmaceuticals, GlaxoSmithKline plc. , AstraZeneca.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with neuropathic pain.

Reasons to BuyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global neuropathic pain market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neuropathic pain market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next huge thing in the global neuropathic pain market landscape? – Identify, know and capitalize.

For more information,please visit:

http://www. aarkstore. com/reports/Neuropathic-Pain-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40530. html

The industry analysis specialist’s new report, “Non-Small Cell Lung Cancer (NSCLC) – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global NSCLC disease market. The report identifies the key trends shaping and driving the global NSCLC disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NSCLC disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by  team of industry experts.  estimates the global NSCLC disease market to be $2. 8 billion in 2008. It is forecast to grow at a compound annual growth rate (CAGR) of 13. 5% for the next seven years to reach $6. 8 billion by 2015. This growth is primarily attributed to increased disease population and strong pipeline with more emerging therapies. The available treatment options are moderately successful in meeting the market demand. There exists a significant market potential to be tapped for any new entrant that will cater to the unmet needs. There is enormous opportunity for any drug that would offer better efficacy provided by the current players with increased safety than the current products. finds that that the emerging therapies in pipeline are expected to increase the competition. Emerging therapies have gained a positive perception among the physicians due to increased efficacy, safety and overall survival. The strong pipeline leads to the stiff competition in the NSCLC market and the existing market leaders need to be prepared to manage this expected dynamism in competition as there is a race to reach the blockbuster drug status. ScopeThe report analyzes market opportunities and challenges for the global NSCLC disease market. Its scope includes – Annualized global NSCLC disease market revenues data from 2000 to 2008, forecast forward for 7 years to 2015. – Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes tyrosine kinase inhibitors, microtubules, protein kinase inhibitors, cell division inhibitors, ERBB3 antagonist, DNA and RNA synthesis inhibitors, C-Met or ALK Inhibitors, glutathione S-transferase binders, growth and survival of MM cells inhibitors, HER2 dimerization inhibitors, antiangiogenesis inhibitors, cyclooxygenase-2 (COX-2) inhibitors, Pan Bcl-2 inhibitors and MUC1 tumor-associated antigens etc. – Analysis of the current and future market competition in the global NSCLC disease market. Key market players covered are F. Hoffmann-La Roche Ltd, Pfizer Inc. , Novartis AG, Sanofi-aventis, Boehringer Ingelheim GmbH, and Abraxis BioScience, Inc. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with NSCLC disease. Reasons to buyThe report will enhance your choice making capability. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global NSCLC disease market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global NSCLC disease market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global NSCLC disease market landscape? – Identify, know and capitalize. ” $2,000 $4,000 $6,000 GDHCPRT020 Pharmaceuticals and Healthcare Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, tyrosine kinase inhibitors, microtubules, protein kinase inhibitors, cell division inhibitors, ERBB3 antagonist, DNA and RNA synthesis inhibitors, C-Met or ALK Inhibitors, glutathione S-transferase binders, growth and survival of MM cells inhibitors, HER2 dimerization inhibitors, antiangiogenesis inhibitors, cyclooxygenase-2 (COX-2) inhibitors, Pan Bcl-2 inhibitors, MUC1 tumor-associated antigens  

For more information,please visit:

http://www. aarkstore. com/reports/Non-Small-Cell-Lung-Cancer-NSCLC-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40590. html

The industry analysis specialist, has released a new report, “Ovarian Cancer – Drug Pipeline Analysis and Market Forecasts to 2016″. The report is an essential source of information and analysis on the global ovarian cancer market. The report identifies the key trends shaping and driving the global ovarian cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ovarian cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. Estimated the global ovarian cancer market to be valued at $697 million in 2009. It is forecast to grow by 13. 1% annually for the next seven years to reach $1,650 million by 2016. This growth is primarily attributed to high prescription rate of existing chemotherapy, strong pipeline and advancement of new targeted therapies. Analyzed that the global ovarian cancer market is moderately served with current product options and significant scope available to new entrants that would capture value from underserved segments. Designing curable products with high efficacy and safety profile is one of key challenges of this market and could provide significant market share for any company.   Analyzed that the global ovarian cancer market is increasingly becoming more competitive. Balancing the pipeline with the current marketed products and expectations of patients and physicians, the pipeline is considered to be strong. The unmet need in ovarian cancer market is high and if a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects. ScopeThe scope of the report includes:

Annualized global ovarian cancer market revenues data from 2001 to 2009, forecast forward 7 years to 2016.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes topoisomerase inhibitor, drugs targeting DNA, vaccines, drugs targeting growth factor and growth factor receptors, folate receptor binder, kinase inhibitor, drugs targeting cytokines and combinations therapy.

Analysis of the current and future market competition in the global ovarian cancer market. Key market players covered are F. Hoffmann-La Roche Ltd/Genentech, Inc. , Menarini Group, Novartis AG, Cell Therapeutics Inc. , Telik, Inc. and BioNumerik Pharmaceuticals Inc.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with ovarian cancer.

Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global ovarian cancer market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global ovarian cancer market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next huge thing in the global ovarian cancer market landscape? – Identify, know and capitalize.

For more information,please visit:

http://www. aarkstore. com/reports/Ovarian-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40533. html

The industry analysis specialist’s new report, “Periodontal disease – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global periodontal disease market. The report identifies the key trends shaping and driving the global periodontal disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global periodontal disease sector.   The global periodontal disease market was valued at $1,248m in 2009 and is characterized by efficacious dental procedures such as scaling, root planing and surgery. The periodontal therapeutics market comprises Local Applied Antibodies (LAAs) and systemic applied antibodies. The influx of new drugs and the increase in the uptake of LAAs will the drive the market in the forecast period. The various phases of the developmental pipeline contain 19 molecules. Of these, only five are in Phase III and the rest are in the early stages of development. The pipeline consists of no new antibiotics. The combinations of the tetracylines are expected to improve the efficacy of the treatment. But, the drug is similar in nature to doxycyclines. The entry of cost effective drugs in the forecast period is expected to aid the market growth.   This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.   Scope  The scope of the report includes:  - Annualized global periodontal disease market revenues data from 2001 to 2009, forecast for seven years to 2016.  - Geographies covered in this report are the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France, and Japan.  - Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include tetracycline antibiotics, osteoblast stimulators and anti-inflammatories, H+/K+ ATPase inhibitors; cell wall synthesis inhibitors.  - Analysis of the current and future market competition in the global periodontal disease market. The key market players covered are Kaken Pharmaceutical, Fibrocell Science, Inc. , and Combinatorx, Inc.  - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.  - Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future periodontal disease market.   Reasons to buy  The report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to: - Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.  - Develop business strategies by understanding the trends shaping and driving the global periodontal disease market.  - Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global periodontal disease market in future.  - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.  - Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.  - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.  - What’s the next huge thing in the global periodontal disease market landscape? – Identify, know and capitalize.  

For more information, please contact :

http://www. aarkstore. com/reports/Periodontal-Disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40454. html

The industry analysis specialist’s new report, “Liver Cancer – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global liver cancer market. The report identifies the key trends shaping and driving the global liver cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global liver cancer sector.   Analyzed that the liver cancer market has high unmet needs in terms of both efficacy and safety. More than 90% of patients diagnosed with liver cancer are between 45 years and 85 years of age. Nexavar is the only available Food and Drug Association (FDA) approved treatment for advanced liver cancer patients. But, the median survival time in patients treated with Nexavar is only three months more than for patients treated with placebo. Moreover, Nexavar has a low safety profile. About 39% and 6% of Nexavar-treated patients reported grade 3 and grade 4 adverse reactions respectively. Therefore, the unmet need in the liver cancer market was valued at 56%. This is expected to decrease significantly between 2009 and 2016 due to the expected launch of many first-in-class and me-too drugs. The majority of the first-in-class drugs are for the early stages of liver cancer and therefore they are expected to treat patients for whom no treatment options currently exist.   This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.   Scope  The scope of the report includes:  - Annualized global liver cancer market revenues data from 2001 to 2009, forecast forward for seven years to 2016.  - Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.  - Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class molecules are primarily Tumor Necrosis Factor Alpha (TNF-alpha) inhibitors, selective estrogen receptor modulators and light activated therapies.  - Analysis of the current and future market competition in the global liver cancer market. Key future market players covered are Bristol-Myers Squibb, Pfizer Inc. , F. Hoffmann-La Roche, Bayer Ag, Onyx Pharmaceuticals, Kowa Pharmaceuticals and Celsion Corporation.  - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.  - Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with the liver cancer market.   Reasons to buy  The report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to: - Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.  - Develop business strategies by understanding the trends shaping and driving the global liver cancer market.  - Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global liver cancer market in future.  - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.  - Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.  - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.  - What’s the next huge thing in the global liver cancer market landscape? – Identify, know and capitalize.

For more information, please contact :

http://www. aarkstore. com/reports/Liver-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40455. html

HIV/AIDS – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV/AIDS market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global HIV/AIDS sector. GlobalData estimated the HIV/AIDS market was worth $12 billion in 2009. The global Human Immunodeficiency Virus (HIV) infection market will continue to grow between 2009 and 2016 at a slower rate due to a series of patent expiries during this period. The growth rate is likely to decline from 2012 onwards due to the impact of the patent expiry of key drugs. The market is characterized by a high unmet need of drugs which can cure the disease. Highly Active Antiretroviral Therapy (HAART) which requires patients to take different classes of drugs has but succeeded in achieving near zero levels of HIV in infected people. Increased uptake of HAART and increasing awareness (which leads to increased treatment seeking) will drive the market. The pipeline for HIV is strong and consists of more than 250 molecules currently in development for various disease segments. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. Scope- Annualized global HIV/AIDS market revenues data from 2001 to 2009, forecast for seven years to 2016. – Geographies covered in this report are the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan. – Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include HIV vaccines, Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), CCR5 receptor antagonists, HIV integrase inhibitors, Nucleoside analogues, Viral entry inhibitors, Maturation inhibitors and Fusion Inhibitors. – Analysis of the current and future market competition in the global HIV/AIDS market. The key market players covered Boehring Ingelheim, Achillion Pharmaceuticals, GlaxoSmithKline, Incyte and Pharmasset, Shire Pharmaceuticals and Tibotec Virco – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future HIV/AIDS market. Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global HIV/AIDS market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global HIV/AIDS market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global HIV/AIDS market landscape? – Identify, know and capitalize

For more information, please contact :

http://www. aarkstore. com/reports/HIV-AIDS-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40849. html